REGENXBIO
REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart fa... ilure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.
REGENXBIO
Industry:
Biopharma Biotechnology Genetics Therapeutics
Founded:
2009-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.regenxbio.com
Total Employee:
251+
Status:
Active
Contact:
(202) 785-7438
Total Funding:
638.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome
Current Advisors List
Board_member
2018-05-01
Board_member
Current Employees Featured
Kenneth Mills Chief Executive Officer, President and Director @ REGENXBIO
Chief Executive Officer, President and Director
2009-02-01
Ken Mills President & Chief Executive Officer @ REGENXBIO
President & Chief Executive Officer
Vit Vasista CFO @ REGENXBIO
CFO
2009-07-01
Curran M. Simpson Senior Vice President of Product Development & Chief Technology Officer @ REGENXBIO
Senior Vice President of Product Development & Chief Technology Officer
Olivier Danos Senior Vice President & Chief Scientific Officer @ REGENXBIO
Senior Vice President & Chief Scientific Officer
Steve Pakola Senior Vice President & Chief Medical Officer @ REGENXBIO
Senior Vice President & Chief Medical Officer
Francesca Cook Vice President, Market Access @ REGENXBIO
Vice President, Market Access
2021-03-01
Ram Palanki Senior Vice President, Commercial Strategy & Operations @ REGENXBIO
Senior Vice President, Commercial Strategy & Operations
2018-08-01
James M. Wilson Founder & Chief Scientific Advisor @ REGENXBIO
Founder & Chief Scientific Advisor
Olivier Danos Chief Scientific Officer @ REGENXBIO
Chief Scientific Officer
2017-03-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-08-25 | Dimension Therapeutics | Dimension Therapeutics acquired by REGENXBIO | N/A |
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - REGENXBIO
RTW Investments LLC
RTW Investments LLC investment in Series D - REGENXBIO
Foresite Capital
Foresite Capital investment in Series D - REGENXBIO
Perceptive Advisors
Perceptive Advisors investment in Series D - REGENXBIO
Sectoral Asset Management
Sectoral Asset Management investment in Series D - REGENXBIO
Venrock
Venrock investment in Series D - REGENXBIO
Cormorant Asset Management
Cormorant Asset Management investment in Series D - REGENXBIO
QVT Financial
QVT Financial investment in Series D - REGENXBIO
F-Prime Capital
F-Prime Capital investment in Series D - REGENXBIO
Tourbillon Global Ventures
Tourbillon Global Ventures investment in Series D - REGENXBIO
Official Site Inspections
http://www.regenxbio.com Semrush global rank: 1.53 M Semrush visits lastest month: 17.31 K
- Host name: 20.231.205.235
- IP address: 20.231.205.235
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "REGENXBIO"
Investors - Regenxbio Inc
May 12, 2025 REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has … See details»
Leadership Team - REGENXBIO
Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company’s Chief Technology and Operations … See details»
REGENXBIO - Crunchbase Company Profile & Funding
REGENXBIO closed its last funding round on Mar 6, 2024 from a Post-IPO Equity round. Who are REGENXBIO 's competitors? Alternatives and possible competitors to REGENXBIO may include … See details»
Regenxbio Inc
Explore Regenxbio Inc's dedication to gene therapy innovation, focusing on retinal, metabolic, and neurodegenerative diseases for transformative patient care. See details»
Regenxbio Inc. - AnnualReports.com
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary … See details»
Who We Are - REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver … See details»
Regenxbio Company Profile - Office Locations, Competitors ... - Craft
Regenxbio has 5 employees at their 1 location and $83.33 m in annual revenue in FY 2024. See insights on Regenxbio including office locations, competitors, revenue, financials, executives, … See details»
A Brief History of REGENXBIO – CanvasBusinessModel.com
Dec 19, 2024 Marked Successes Along the Way. Since its inception, REGENXBIO has achieved numerous milestones and marked successes in the field of adeno-associated viral vector-based … See details»
Nippon Shinyaku and REGENXBIO Enter into an Exclusive Partnership …
Jan 13, 2025 For RGX-121, REGENXBIO has received Fast Track Designation, Rare Pediatric Disease Designation, Regenerative Medicine Advanced Therapy Designation, and Orphan Drug … See details»
Management Team - REGENXBIO
Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company’s Chief Operating … See details»
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership …
Jan 14, 2025 REGENXBIO to receive $110 million upfront, ... happier lives," we aim to be an organization trusted by the community through creating unique medicines that will bring hope to … See details»
REGENXBIO - Contacts, Employees, Board Members, Advisors
Organization. REGENXBIO . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 16. Number of Board Member … See details»
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial …
Dec 31, 2024 Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for … See details»
Regenxbio's RGX-121 Could Become The New Standard Of Care In …
13 hours ago Regenxbio (NASDAQ:RGNX) is a clinical-stage biopharmaceutical company focusing on gene therapies. Founded in 2008, the core technology of the company is the delivery of rescue … See details»
Investors & Newsroom - REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Contact Us Terms and Conditions See details»
REGENXBIO - Funding, Financials, Valuation & Investors - Crunchbase
REGENXBIO is registered under the ticker NASDAQ:RGNX . Their stock opened with $22.00 in its Sep 8, 2015 IPO. Stock Symbol NASDAQ:RGNX ; Valuation at IPO $492M; Money Raised at IPO … See details»
Mission & Values - REGENXBIO
REGENXBIO is on a mission to improve lives through the curative potential of gene therapy. Gene therapy has the potential to address the underlying cause of disease, providing single-dose … See details»
REGENXBIO Announces Closing of Strategic Partnership with Nippon ...
Mar 4, 2025 REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. ... "Helping people lead healthier, happier … See details»
Board of Directors - REGENXBIO
Ken Mills served as the founding President and Chief Executive Officer of REGENXBIO from 2009-2024, and is now Chairman of the Board of Directors. Mr. Mills led REGENXBIO’s initial public … See details»
Regenxbio’s Duchenne Gene Therapy Study Results Suggest Future …
1 day ago Children with a deadly muscle disorder had more control of their bodies after getting an experimental gene therapy from Regenxbio Inc. in a small study. The results foreshadow a … See details»